Merit Medical Announces 2Q 2007 Results


SOUTH JORDAN, Utah, July 26, 2007 (PRIME NEWSWIRE) -- Merit Medical Systems, Inc. (Nasdaq:MMSI), a leading manufacturer and marketer of proprietary disposable devices used primarily in cardiology and radiology procedures, today announced record revenues of $51.8 million for its second quarter ended June 30, 2007, compared with $48.1 million for the second quarter of 2006, an increase of 8%. Revenues for the six-month period ended June 30, 2007 were a record $102.8 million, compared with $93.1 million for the same six-month period in 2006, a gain of 10%.

Net income for the second quarter ended June 30, 2007 was $3.6 million, or $0.13 per share, compared to $3.5 million, or $0.13 per share, for the comparable quarter of 2006. Net income for the six-month period ended June 30, 2007 was $6.6 million, or $0.23 per share, compared to $5.9 million, or $0.21 per share, for the same period of 2006.

"Although sales were slower than expected for the quarter, we are pleased with the improvement in gross and operating margins and the resulting earnings, which were 21 percent higher than in the first quarter of 2007," said Fred P. Lampropoulos, Merit's Chairman and Chief Executive Officer. "We are aware of the lower interventional procedure rate being reported by other companies, and we will continue to evaluate our overall prospects for the year and report, if necessary, any changes in our projections."

"Many of our cost savings and efficiency projects such as the automated packaging equipment in three facilities, off-shore manufacturing, overall headcount reductions and other projects are online and expected to impact our cost structure going forward," Lampropoulos added.

"A number of new products such as our CT transfer sets, the FZ Depot(tm) collection bag and our 'Meritized' ProGuide(tm) dialysis catheter, which was recently cleared for European sales, were introduced in the second quarter," Lampropoulos continued. "New product introductions such as our All-Star(tm) hemostasis valve, the Sea Dragon(tm) torque device, the 4 French Impress(r) catheters and our recently announced Prelude(r) transradial sheath are scheduled for release during the balance of 2007."

All product categories of Merit's business contributed to revenue growth in the second quarter of 2007, with catheter sales increasing 20%; custom kit and tray sales rising 9%; stand-alone device sales growing 7%; and inflation device sales increasing 2%.

For the six-month period ended June 30, 2007, catheter sales increased 19%; custom kits and tray sales rose 14%; stand-alone device sales grew 13%; and inflation device sales increased 1%.

Gross margins for the second quarter of 2007 were 37.7% of sales, compared to 39.5% of sales for the second quarter of 2006. Gross margins for the six-month period ended June 30, 2007 were 37.3% of sales, compared to 38.7% of sales for the same period of 2006. The decrease in gross margins for the second quarter and six-month period ended June 30, 2007 can be attributed primarily to an increase in wages beginning in the fourth quarter of 2006, increased production headcount, additional write-off of obsolete inventory, an increase in the sales of a lower-margin product to an OEM customer, and higher health care costs.

Selling, general and administrative expenses for the second quarter of 2007 were 22.9% of sales, compared to 23.9% of sales for the second quarter of 2006. For the six-month period ended June 30, 2007, selling, general and administrative expenses were 23.2% of sales, compared with 24.4% of sales for the first six months of 2006.

Research and development costs during the second quarter of 2007 were 4.3% of sales, compared to 4.2% of sales for the second quarter of 2006. Research and development costs were 4.4% of sales for the first six months of 2006 and 2007.

Income from operations was $5.5 million, for both the second quarter of 2007 and the second quarter of 2006. For the six-month period ended June 30, 2007, income from operations was $10.0 million, compared to $9.2 million for the same period of 2006.

Merit's effective tax rate for the second quarter of 2007 was 35.0%, compared with 35.7% for the second quarter of 2006. For the six-month period ended June 30, 2007, Merit's effective tax rate was 35.0%, compared to 35.8% for the same period of 2006.

Conference Call

Merit Medical invites all interested parties to participate in its conference call today, July 26th, at 5:00 p.m. Eastern (4:00 p.m. Central, 3:00 p.m. Mountain, and 2:00 p.m. Pacific). The domestic phone number is 800-866-5043, and the international number is 303-262-2005. A live webcast as well as a rebroadcast can be accessed through the webcast tab of the Investors page at www.merit.com or through the webcasts tab at www.fulldisclosure.com.



 INCOME STATEMENT
 (Unaudited, in thousands except per share data)

                     Three Months Ended            Six Months Ended
                          June 30,                     June 30,
                 ------------------------    -------------------------
                       2007          2006         2007           2006
                 -------------------------   -------------------------

 SALES           $    51,811   $    48,121   $   102,841   $    93,161

 COST OF SALES        32,275        29,125        64,447        57,114
                 -----------   -----------   -----------   -----------
 GROSS PROFIT         19,536        18,996        38,394        36,047

 OPERATING
  EXPENSES
   Selling,
   general and
   administrative     11,858        11,497        23,873        22,764
  Research and
   development         2,207         2,023         4,571         4,102
                 -----------   -----------   -----------   -----------
   Total              14,065        13,520        28,444        26,866

 INCOME FROM
  OPERATIONS           5,471         5,476         9,950         9,181

 OTHER INCOME
  (EXPENSE)
   Interest
    income               63            64           152           110
   Other
   (expense)             (1)          (67)           (2)          (65)
                 -----------   -----------   -----------   -----------
    Total Other
    (expense)
    income - net          62            (3)          150            45

 INCOME BEFORE
  INCOME TAX
  EXPENSE              5,533         5,473        10,100         9,226

 INCOME TAX
  EXPENSE              1,937         1,951         3,535         3,303
                 -----------   -----------   -----------   -----------

 NET INCOME      $     3,596   $     3,522   $     6,565   $     5,923
                 -----------   -----------   -----------   -----------

 EARNINGS PER
  SHARE-
   Basic         $      0.13   $      0.13   $      0.24   $      0.22
                 ===========   ===========   ===========   ===========

   Diluted       $      0.13   $      0.13   $      0.23   $      0.21
                 ===========   ===========   ===========   ===========

 AVERAGE COMMON
  SHARES-
   Basic          27,727,055    27,260,928    27,690,218    27,228,481
                 ===========   ===========   ===========   ===========

   Diluted        28,480,161    27,966,729    28,548,583    28,029,595
                 ===========   ===========   ===========   ===========


  BALANCE SHEET
 (Unaudited in thousands)
                                              June 30,   December 31,
                                                2007         2006
                                             ---------   -----------
 ASSETS
 Current Assets
   Cash and cash equivalents                 $   9,281    $   9,838
   Trade receivables, net                       25,029       25,745
   Employee receivables                            133          194
   Other receivables                               734          192
   Inventories                                  38,373       38,562
   Prepaid expenses and other assets             1,702        1,031
   Deferred income tax assets                        3            2
   Income tax refunds receivable                   188           82
                                             ---------    ---------
     Total Current Assets                       75,443       75,646

 Property and equipment, net                    97,697       92,383
 Other intangibles, net                          5,369        4,350
 Goodwill                                        9,068        7,541
 Other assets                                    2,921        2,656
 Deferred income tax assets                         14            2
 Deposits                                           84           90
                                             ---------    ---------
 Total Assets                                $ 190,596    $ 182,668
                                             =========    =========

 LIABILITIES AND STOCKHOLDERS' EQUITY
 Current Liabilities
   Trade payables                               11,140       10,598
   Accrued expenses                              9,794        8,464
   Advances from employees                         312          245
   Deferred income tax liabilities                  --          190
   Income taxes payable                            401        1,177
                                             ---------    ---------
    Total Current Liabilities                   21,647       20,674

 Deferred income tax liabilities                 4,812        5,469
 Liabilities related to unrecognized tax 
  positions                                      3,857           --
 Deferred compensation payable                   3,022        2,869
 Deferred credits                                2,167        2,239
 Other long-term obligations                       528          205
                                             ---------    ---------
    Total Liabilities                           36,033       31,456

 Stockholders' Equity
   Common stock                                 51,755       54,394
   Retained earnings                           102,925       96,969
   Accumulated other comprehensive loss           (117)        (151)
                                             ---------    ---------
    Total stockholders' equity                 154,563      151,212

                                             ---------    ---------
 Total Liabilities and Stockholders' Equity  $ 190,596    $ 182,668
                                             =========    =========

About Merit

Founded in 1987, Merit Medical Systems, Inc. is engaged in the development, manufacture and distribution of proprietary disposable medical devices used in interventional and diagnostic procedures, particularly in cardiology and radiology. Merit serves client hospitals worldwide with a domestic and international sales force totaling approximately 90 individuals. Merit employs approximately 1,700 people worldwide, with facilities in Salt Lake City and South Jordan, Utah; Santa Clara, California; Angleton, Texas; Richmond, Virginia; Maastricht and Venlo, The Netherlands; and Galway, Ireland.

The Merit Medical Systems, Inc. logo is available at http://www.primenewswire.com/newsroom/prs/?pkgid=3282

Statements contained in this release, which are not purely historical, are forward-looking statements within the meaning of the Private Securities Litigation Act of 1995 and are subject to risks and uncertainties such as those described in Merit's Annual Report on Form 10-K for the year ended December 31, 2006. Such risks and uncertainties include product recalls and product liability claims; infringement of Merit's technology or the assertion that Merit's technology infringes the rights of other parties; termination of relationship with suppliers, or failure of suppliers to perform; inability to successfully manage growth through acquisitions; delays in obtaining regulatory approvals, or the failure to maintain such approvals; significant portions of our revenues being derived from a few products and procedures; development of new products and technology that could render Merit's products obsolete, market acceptance of new products, introduction of products in a timely fashion, price and product competition, availability of labor and materials, cost increases, and fluctuations in and obsolescence of inventory; market price of our common stock has been and may continue to be volatile; foreign currency fluctuations; key personnel; work stoppage or transportation risks; modification or limitation of governmental or private insurance reimbursement, changes in health care markets related to health care reform initiatives; and other factors referred to in Merit's most recent 10-K and other reports filed with the Securities and Exchange Commission. All subsequent forward-looking statements attributable to Merit or persons acting on its behalf are expressly qualified in their entirety by these cautionary statements. Actual results may differ materially from anticipated results. Financial estimates are subject to change and are not intended to be relied upon as predictions of future operating results, and Merit assumes no obligation to update or disclose revisions to those estimates.



            

Contact Data